If most newly diagnosed SMA patients’ parents opt for one-time gene replacement therapy, only clinical measures and blood NfL levels would be available to forecast variability in outcomes including poor improvement seen in older children. This evidence concerns the gene NEFL and proximal spinal muscular atrophy.